Argenx Se ADR (ARGX) Stock Price, Quote & News

Company Profile

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren'...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 10 703 8441

Website: argenx.com

Address:

Laarderhoogtweg 25, Amsterdam, Netherlands

Skies88 Jul. 2 at 5:21 PM

$ARGX Seriously! This went down to $510 on the news because everyone knows it is the incoming law suits for lack of full disclosure that is the issue. FDA will get them to correct that for new patients but for the existing incidents it will be a class action lawsuit. Until FDA sends back a detailed response on the action to take everything is unknown.

0 · Reply

SparkyReturns Jul. 2 at 2:39 PM

$VRTX Investing idea. Anyone remember when I gave this tip about ICU a few times in the last week...? Yeah. $REGN $ALNY $ARGX

0 · Reply

Skies88 Jul. 2 at 1:57 PM

$ARGX Well ..... This is on several cases and they need to take an action - FDA will be out with a "regulatory action" soon. Argenx SE (NASDAQ:ARGX) U.S. Food and Drug Administration (FDA) signaled serious risks/safety identified by the reporting system for Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase). The FDA highlighted the severe worsening of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). CIDP is an immune-mediated polyneuropathy marked by nerve roots and peripheral nerve inflammation.

1 · Reply

Travis1013 Jul. 1 at 5:02 PM

$ARGX https://www.biospace.com/business/argenx-makes-1-5b-play-for-unps-macrocyclic-peptides-aimed-at-undruggable-targets?utm_campaign=5458739-2025%20%7C%20Daily%20Social&utm_content=336995502&utm_medium=social&utm_source=linkedin&hss_channel=lcp-424124

0 · Reply

Skies88 Jul. 1 at 2:29 PM

$ARGX What a fraud. Ignoring the bad news from the FDA? This will dump when law suits hit. "Argenx SE (NASDAQ:ARGX) U.S. Food and Drug Administration (FDA) signaled serious risks/safety identified by the reporting system for Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase). The FDA highlighted the severe worsening of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). CIDP is an immune-mediated polyneuropathy marked by nerve roots and peripheral nerve inflammation."

1 · Reply

JarvisFlow Jul. 1 at 11:00 AM

HC Wainwright & Co. has adjusted their stance on argenx ( $ARGX ), setting the rating to Buy with a target price of 720.

0 · Reply

JarvisFlow Jun. 30 at 8:31 PM

Guggenheim has updated their rating for argenx ( $ARGX ) to Buy with a price target of 775.

0 · Reply

NorthstarT1D Jun. 30 at 8:11 PM

$ARGX AI trading seriously gone wrong here today. Just a routine update of the FDA AE posting and AI bots started producing panic-inducing articles. Good buying opportunity today though, added 20% to my position while it dipped

2 · Reply

Skies88 Jun. 30 at 7:35 PM

$ARGX Argenx SE (NASDAQ:ARGX) stock is trading lower on Monday after the U.S. Food and Drug Administration (FDA) signaled serious risks/safety identified by the reporting system for Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase).

0 · Reply

Skies88 Jun. 30 at 7:35 PM

$ARGX

0 · Reply

FDA Flags Major Safety Concerns For Argenx's Nerve Disorder Drug, Stock Falls

Jun 20, 2025, 1:00 PM EDT - 21 days ago

argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy

Jun 10, 2025, 6:01 PM EDT - 4 weeks ago

argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease

Jun 3, 2025, 1:00 AM EDT - 5 weeks ago

argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference

May 28, 2025, 4:01 PM EDT - 6 weeks ago

argenx Announces Results of Annual General Meeting of Shareholders

May 9, 2025, 8:02 AM EDT - 2 months ago

Argenx Q1 Earnings: Less Than Perfect Report Gets Punished

May 8, 2025, 8:16 PM EDT - 2 months ago

argenx SE (ARGX) Q1 2025 Earnings Call Transcript

May 8, 2025, 1:00 AM EDT - 2 months ago

argenx Reports First Quarter 2025 Financial Results and Provides Business Update

May 6, 2025, 1:00 AM EDT - 2 months ago

argenx to Present at BofA Securities 2025 Health Care Conference

May 1, 2025, 1:00 AM EDT - 2 months ago

argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025

Apr 28, 2025, 1:00 AM EDT - 2 months ago

argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Apr 11, 2025, 5:41 PM EDT - 3 months ago

FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting

Apr 11, 2025, 4:01 PM EDT - 3 months ago

argenx Announces Annual General Meeting of Shareholders on May 27, 2025

Apr 10, 2025, 5:59 PM EDT - 3 months ago

US FDA approves syringe version of Argenx's immune disorder drug

Apr 10, 2025, 5:47 PM EDT - 3 months ago

argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

Apr 8, 2025, 1:00 AM EDT - 3 months ago

argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP

Apr 4, 2025, 2:30 PM EDT - 3 months ago

Stock Picks From Seeking Alpha's March 2025 New Analysts

AI CCL CEPU CF CROX CUK DECK

Mar 7, 2025, 1:00 AM EST - 4 months ago

argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting

Feb 27, 2025, 3:17 PM EST - 4 months ago

argenx SE (ARGX) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 11:58 AM EST - 4 months ago

argenx: Vyvgart's Sales Momentum Improves, Clinical Data Updates From A Key Competitor Imminent

Feb 27, 2025, 1:00 AM EST - 4 months ago

argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update

Feb 25, 2025, 1:00 AM EST - 4 months ago

argenx to Present at TD Cowen 45th Annual Healthcare Conference

Feb 20, 2025, 1:00 AM EST - 5 months ago

argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025

Jan 13, 2025, 1:00 AM EST - 6 months ago

argenx Highlights 2025 Strategic Priorities

Jan 6, 2025, 1:00 AM EST - 6 months ago

argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 27, 2024, 1:00 AM EST - 7 months ago

argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

Nov 26, 2024, 1:00 AM EST - 8 months ago

argenx to Present at Upcoming Investor Conferences

Nov 20, 2024, 1:00 AM EST - 8 months ago

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

Nov 19, 2024, 9:10 AM EST - 8 months ago

Steritas Announces Collaboration with argenx to Advance Evidence for Novel Steroid-sparing Therapeutics

Nov 11, 2024, 7:30 AM EST - 8 months ago

argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

Nov 11, 2024, 7:30 AM EST - 8 months ago

Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

ZLAB

Nov 5, 2024, 1:00 AM EST - 8 months ago

argenx to Participate at Upcoming Investor Conferences

Oct 31, 2024, 1:29 PM EDT - 9 months ago

Argenx: Strong CIDP Launch, But gMG Growth Propels Q3 Sales Beat

Oct 31, 2024, 1:08 PM EDT - 9 months ago

argenx SE (ARGX) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 2:00 AM EDT - 9 months ago

argenx Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 24, 2024, 1:00 AM EDT - 9 months ago

argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024

Oct 15, 2024, 1:00 AM EDT - 9 months ago

argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions

Sep 24, 2024, 9:06 PM EDT - 10 months ago

argenx: Myositis Data Could Add Billions In Value

Sep 19, 2024, 1:00 AM EDT - 10 months ago

argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy

Aug 12, 2024, 5:13 PM EDT - 11 months ago

Biotech stocks: Which drugmakers are worth a buy?

NVCR

Jul 25, 2024, 1:00 AM EDT - 1 year ago

argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update

Jul 18, 2024, 1:00 AM EDT - 1 year ago

argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024

Jul 16, 2024, 12:30 AM EDT - 1 year ago

argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

Jul 16, 2024, 12:15 AM EDT - 1 year ago

Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

ZLAB

Jun 28, 2024, 10:20 AM EDT - 1 year ago

Argenx: Strong Setup For Outperformance In 2025

Jun 25, 2024, 4:30 PM EDT - 1 year ago

argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting

Jun 24, 2024, 12:43 PM EDT - 1 year ago

Why Is European Drugmaker Argenx Stock Trading Higher On Monday?

Jun 21, 2024, 4:50 PM EDT - 1 year ago

argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy

Jun 17, 2024, 1:00 AM EDT - 1 year ago

argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients' during its Upcoming R&D Day on July 16, 2024

Skies88 Jul. 2 at 5:21 PM

0 · Reply

SparkyReturns Jul. 2 at 2:39 PM

$VRTX Investing idea. Anyone remember when I gave this tip about ICU a few times in the last week...? Yeah. $REGN $ALNY $ARGX

0 · Reply

Skies88 Jul. 2 at 1:57 PM

1 · Reply

Travis1013 Jul. 1 at 5:02 PM

0 · Reply

Skies88 Jul. 1 at 2:29 PM

1 · Reply

JarvisFlow Jul. 1 at 11:00 AM

HC Wainwright & Co. has adjusted their stance on argenx ( $ARGX ), setting the rating to Buy with a target price of 720.

0 · Reply

JarvisFlow Jun. 30 at 8:31 PM

Guggenheim has updated their rating for argenx ( $ARGX ) to Buy with a price target of 775.

0 · Reply

NorthstarT1D Jun. 30 at 8:11 PM

2 · Reply

Skies88 Jun. 30 at 7:35 PM

0 · Reply

Skies88 Jun. 30 at 7:35 PM

$ARGX

0 · Reply

CDMO Jun. 30 at 6:48 PM

$ARGX the fck was that? Added some

0 · Reply

Monkey_Banana_Genius Jun. 30 at 4:04 PM

$ARGX the timing here was

1 · Reply

NorthstarT1D Jun. 30 at 3:49 PM

$ARGX wtf happened here....

1 · Reply

Monkey_Banana_Genius Jun. 30 at 3:07 PM

$ARGX selling this for small gain. Still like it but running out of cash so this gonna be sacrificed.

1 · Reply

DonCorleone77 Jun. 30 at 10:20 AM

$ARGX Argenx announces plan to advance clinical development of ARGX-119 Argenx announced its plan to advance the clinical development of ARGX-119, an agonist antibody to muscle-specific kinase, to a registrational study in patients with congenital myasthenic syndromes following the analysis of topline data from the Phase 1b study. Detailed results will be presented at a future medical meeting.

0 · Reply

Travis1013 Jun. 25 at 4:09 PM

$ARGX Simply Wall St’s current valuation!😳😳😳

0 · Reply

ChessGM Jun. 24 at 6:30 PM

$ARGX Wedbush Reiterates Outperform on argenx, Maintains $715 Price Target

0 · Reply

Monkey_Banana_Genius Jun. 24 at 6:24 PM

$ARGX who YO daddy? LONG

0 · Reply

CDMO Jun. 23 at 5:21 PM

$ARGX added some

1 · Reply

stieveling Jun. 23 at 3:04 PM

$ARGX

0 · Reply

mikesterz7 Jun. 21 at 6:18 PM

$ARGX Argenx Gets European Commission Approval For Drug To Treat Rare Autoimmune Disease

0 · Reply

Bcscoatings Jun. 20 at 7:30 PM

$ARGX great news out here and H C sets a higher target price!!! $PCSA also big news out and hitting hard right now high volume pushing this

0 · Reply

Market Cap	34.40B
Revenue (ttm)	2.25B
Net Income (ttm)	833.04M
EPS (ttm)	N/A
PE Ratio	92.53
Forward PE	43.92
Profit Margin	36.99%
Debt to Equity Ratio	0.00

Volume	248,400
Avg Vol	424,746
Day's Range	N/A - N/A
Shares Out	61.06M
Stochastic %K	86%
Beta	0.37
Analysts	Strong Sell
Price Target	$744.64